By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Keryx Biopharmaceuticals 

750 Lexington Avenue, 26th Floor

New York  New York  10022  U.S.A.
Phone: 212-531-5965 Fax: 212-531-5961


SEARCH JOBS


Industry
Biotechnology






Company News
Keryx Biopharmaceuticals (KERX) To Present At The Oppenheimer 25th Annual Healthcare Conference 12/8/2014 8:14:35 AM
Keryx Biopharmaceuticals (KERX) Announces Issuance Of A New U.S. Patent For Auryxia (Ferric Citrate) Covering Orally Administrable Forms 12/4/2014 4:37:33 PM
Keryx Biopharmaceuticals (KERX) Release: Auryxia (Ferric Citrate) Phase 2 Data Published In The American Journal Of Kidney Disease 12/2/2014 1:34:56 PM
Keryx Biopharmaceuticals (KERX) Announces Trade Name Auryxia for Ferric Citrate 11/19/2014 9:18:53 AM
Keryx Biopharmaceuticals (KERX) Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 11/17/2014 10:32:03 AM
Keryx Biopharmaceuticals (KERX) To Present At The Stifel 2014 Healthcare Conference 11/14/2014 10:16:34 AM
Keryx Biopharmaceuticals (KERX) Announces Third Quarter And Nine Month 2014 Financial Results 11/6/2014 10:53:07 AM
Keryx Biopharmaceuticals (KERX) To Host Conference Call On Third Quarter 2014 Financial Results 10/30/2014 8:37:08 AM
Keryx Biopharmaceuticals (KERX) Announces Issuance Of A New U.S. Patent For Ferric Citrate Covering Orally Administrable Forms 10/1/2014 8:55:44 AM
Keryx Biopharmaceuticals (KERX) Initiates Pivotal Phase 3 Study Of Ferric Citrate For The Treatment Of Iron Deficiency Anemia In Patients With Non-Dialysis Dependent Chronic Kidney Disease 9/29/2014 8:57:11 AM
12345678910...
//-->